Although significant progress has been made in the diagnosis and treatment of gastric cancer, the overall survival rate of the disease remains unchanged at approximately 20%-25%. Thus, there is an urgent need for a better understanding of the molecular biology aspects of the disease in the hope of discovering novel diagnosis and treatment strategies. Recent years have witnessed decisive roles of aberrant cancer cell metabolism in the maintenance of malignant hallmarks of cancers, and cancer cell metabolism has been regarded as a novel target for the treatment of cancer. CDK2, a cell cycle-dependent kinase that usually regulates cell cycle progression and the DNA damage response, is reported to be upregulated in many cancers. However, little is known about its role in cancer cell metabolism. In the present study, we showed that silencing CDK2 inhibited the aerobic glycolytic capacity of gastric cancer cell lines. Mechanism explorations showed that silencing CDK2 increased expression of the SIRT5 tumor suppressor. In addition, the physiological roles of SIRT5 in the regulation of proliferation and glycolysis were studied in gastric cancer cells. Taken together, the present study uncovered novel roles of the CDK2/SIRT5 axis in gastric cancer and suggests future studies concerning gastric cancer cell metabolism.
| INTRODUCTION
Gastric cancer is one of the most common types of cancer and ranks second in cancer-related deaths worldwide. 1 Although significant progress has been made in the diagnosis and treatment of this cancer, only modest progress has been made in improving gastric cancerrelated mortality. 2 Furthermore, estimates suggest that the gastric cancer-related death rate will continue to increase. 3 Thus, there is an urgent need to identify novel biomarkers that could be used to predict prognosis and elucidate the underlying molecular mechanisms. 4 Ninety years ago, Otto Warburg published a series of works linking metabolism and cancer through enhanced aerobic glycolysis (also known as the Warburg effect) that distinguishes cancer from normal tissues. 5 With further studies, aberrant cancer cell metabolism came to be regarded as one of the hallmarks of cancer. 6 It is known that solid tumors reside in a microenvironment with limited oxygen and nutrient supplies and that to survive in such a hostile microenvironment, tumor cells must shift their metabolism pattern. 7 The best characterized cancer cell metabolism process is glucose metabolism. Under hypoxia conditions, cancer cells shift their metabolism to glycolysis. From the ATP generation aspect, the process of glycolysis is not highly efficient because only 2 ATP are generated. However, through glycolysis, Zhenyong Tang and Lei Li contributed equally to this work.
cancer cells use glucose to form building blocks for macromolecule synthesis. 8 Furthermore, lactic acid can be produced by glycolysis, and accumulated lactic acid can cause an acidic microenvironment. The extracellular matrix becomes quite unstable under acidic conditions, facilitating the metastasis of cancer cells. 9, 10 This information led to the hypothesis that targeting cancer cell metabolism might aid in the discovery of novel strategies against cancer. T A B L E 1 Primer sequences of genes examined in the present study
Expressions of designated genes were determined by quantitative realtime PCR. All reactions were run in triplicate. GLUT1, glucose transporter 1; HK2, hexokinase 2; LDHA, lactate dehydrogenase A; PDK1, pyruvate dehydrogenase kinase 1.
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| 5(6)-Carboxyfluorescein diacetate

N-succinimidyl ester cell proliferation assay
In order to measure the impact of CDK2 on cell viability and the proliferation of gastric cancer cells, the 5(6)-carboxyfluorescein diacetate N-succinimidyl ester (CFSE) cell proliferation assay was carried out. In brief, cells cultured in 6-well plates were labeled using CFSE (SigmaAldrich, St Louis, MO, USA) at a final concentration of 5 μmol/L.
Stained cells were measured using a flow cytometer (BD Biosciences, San Jose, CA, USA) at 488 nm excitation after 1, 2, 3, and 4 days separately. Data were analyzed using Flowing Software (University of Turku, Finland).
| Colony formation assay
Gastric cancer cells (5 × 10 2 ) stably expressing shRNA targets against CDK2, and the relevant control cells were seeded into 6-well plates.
The cells were cultivated for 14 days, and then 4% paraformaldehyde was used to fix the cells. Cells were then stained with 1% crystal violet. Colonies were counted using bright field microscopy.
| Cell apoptosis measurement
To examine the impact of SIRT5 on apoptosis of gastric cancer cells, the Annexin V-FITC Apoptosis Detection Kit (Yeason, Shenzhen, Guangdong, China) was used. The assay was carried out according to protocols provided by the supplier.
| Glycolysis assessment
To examine the effect of CDK2 on aerobic glycolysis of gastric cancer cells, the Seahorse Bioscience XF96 Extracellular Flux Analyzer was used (Seahorse Bioxcience, Billerica, MA, USA). Cellular glycolysis capacity was measured by testing the extracellular acidification rate (ECAR). Mitochondrial respiration capacity was measured by testing the oxygen consumption rate (OCR). All the assays were carried out according to the manufacturer's protocols.
| Statistical analyses
Statistical analyses were carried out using SPSS software (version 17.0; IBM Corp., Armonk, NY, USA) using independent t tests (for continuous variables) and Pearson's χ 2 tests (for categorical variables). Statistical significance was based on 2-sided P-values of < 0.05.
| RESULTS
| CDK2 positively regulated aerobic glycolysis in gastric cancer
To observe the role of CDK2 in gastric cancer cell metabolism, we first silenced CDK2 expression in the gastric cancer cell lines SGC-7901 and MGC-803. Efficacy of the silencing effect was confirmed by western blot analysis ( Figure 1A,B) . Then, we assessed the impact of CDK2 silencing on the glycolysis rate. As shown, silencing CDK2 expression significantly inhibited ECAR levels, indicating that CDK2
is a positive regulator of aerobic glycolysis ( Figure 1C,D 
| DISCUSSION
In the present study, we showed that the cell cycle regulator CDK2 Sirtuin family members are key regulators of aging, mitochondriarelated processes and reactive oxygen species (ROS) generation. 28 Among them, SIRT3, SIRT4 and SIRT5 localize to the mitochondria and are reported to play negative roles in tumor formation and progression. 29 For example, the deletion or decreased expression of SIRT3 has been observed in breast cancer cells. Decreased SIRT3 expression increased ROS generation, leading to HIF1α stabilization and enhanced glycolysis. 30 SIRT4 has been reported to regulate glutamine and glucose metabolism in cancer cells. 31 Furthermore, SIRT4 has been reported to regulate cancer cell metabolism in response to genotoxic stress. 32 SIRT5 has been reported to be a negative regulator of metabolism, but its impact on cancer, especially gastric cancer, has seldom been reported. In our study, we indicated that SIRT5 plays a negative role in gastric cancer cell metabolism and proliferation. The underlying molecular mechanism requires further investigation. Previous studies showed that SIRT5 could bind, desuccinylate and activate Cu/Zn superoxide dismutase (SOD1) to scavenge ROS generation. 33 As discussed above, decreased ROS could inhibit glycolysis. Thus, it is necessary to examine the impact of SIRT5 on ROS generation in gastric cancer cells. Moreover, the underlying molecular mechanism might reside in the impact of SIRT5 on the activity of glycolysis genes. For | 2597 example, tumor cells tend to express higher levels of pyruvate kinase M2 (PKM2). PKM2 could be activated by succinylation at lysine 498 (K498). SIRT5 could bind and desuccinylate PKM2, inhibiting its activity. 34, 35 Thus, further investigations are needed to examine the desuccinylating roles of SIRT5 in gastric cancer.
In conclusion, our present study uncovered novel functions of CDK2 and SIRT5 in gastric cancer and may shed light on novel therapeutic and prognostic markers, with the aim of improving the overall survival of gastric cancer patients.
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